
We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Capricor Therapeutics, Inc. is a San Diego based biotechnology company focused on the development of transformative cell and exosome-based therapeutics for the treatment and prevention of muscular and other select diseases. Capricor's lead candidate, CAP-1002, is an allogeneic cardiac-derived cell t... Capricor Therapeutics, Inc. is a San Diego based biotechnology company focused on the development of transformative cell and exosome-based therapeutics for the treatment and prevention of muscular and other select diseases. Capricor's lead candidate, CAP-1002, is an allogeneic cardiac-derived cell therapy that is currently in late-stage clinical development for treating Duchenne muscular dystrophy (DMD). Capricor is also developing its exosome technology as a next-generation therapeutic platform. Capricor's proprietary StealthX¿ exosome platform has potential for a broad range of new therapeutic applications in the field of vaccinology as well as targeted oligonucleotide, protein and small molecule therapeutics to treat or prevent a variety of diseases. Show more
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -1.2551 | -9.46887966805 | 13.255 | 15 | 11.7 | 2034806 | 13.64010951 | CS |
4 | 2.4349 | 25.4563512807 | 9.565 | 15 | 9.0708 | 2153623 | 11.56371634 | CS |
12 | -2.1601 | -15.2549435028 | 14.16 | 15 | 6.27 | 2229631 | 9.89630396 | CS |
26 | -2.2301 | -15.6718200984 | 14.23 | 16.465 | 6.27 | 1690081 | 11.35655526 | CS |
52 | 6.9499 | 137.621782178 | 5.05 | 23.4 | 3.52 | 1806832 | 12.67552791 | CS |
156 | 8.0499 | 203.794936709 | 3.95 | 23.4 | 2.68 | 728042 | 11.30702918 | CS |
260 | 7.4999 | 166.664444444 | 4.5 | 23.4 | 2.56 | 747605 | 9.03575125 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions